Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-01-11

Clinical Trial Update: A Phase II Study of Pemetrexed and Carboplatin in the Treatment of Esophageal Cancer [Phase 2]

View source ↗

Summary

Phase II study evaluating pemetrexed with carboplatin for esophageal cancer was terminated, with results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alimta (pemetrexed)
  • CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Esophageal Neoplasms | Phase 2 | Status: TERMINATED | Results posted: 2016-01-11